Direkt zum Inhalt
Merck

P3043

Sigma-Aldrich

β-Propiolacton

Grade III, 85-90%

Synonym(e):

3-Hydroxypropionsäure-lacton, Hydracrylsäure-β-lacton

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C3H4O2
CAS-Nummer:
Molekulargewicht:
72.06
EG-Nummer:
MDL-Nummer:
UNSPSC-Code:
12352200

Typ

Grade III

Assay

85-90%

Brechungsindex

n20/D 1.412 (lit.)

bp

162 °C (lit.)

mp (Schmelzpunkt)

−33 °C (lit.)

Dichte

1.146 g/mL at 25 °C (lit.)

Lagertemp.

2-8°C

SMILES String

O=C1CCO1

InChI

1S/C3H4O2/c4-3-1-2-5-3/h1-2H2

InChIKey

VEZXCJBBBCKRPI-UHFFFAOYSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Vorsicht

Insoluble polymers may form during storage.

Piktogramme

Skull and crossbonesHealth hazard

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 2 Inhalation - Carc. 1B - Eye Irrit. 2 - Skin Irrit. 2

Lagerklassenschlüssel

6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flammpunkt (°F)

158.0 °F - closed cup

Flammpunkt (°C)

70 °C - closed cup

Persönliche Schutzausrüstung

Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

H J M Jagt et al.
Biologicals : journal of the International Association of Biological Standardization, 38(1), 128-134 (2009-09-01)
An in vitro potency test has recently been included in the European Pharmacopoeia (EP) monograph (01/2007:0870) to assess the potency of inactivated Newcastle disease (ND) vaccines. This enzyme linked immunosorbent assay (ELISA) is an attractive alternative for the existing in
Natalija Budimir et al.
PloS one, 7(1), e30898-e30898 (2012-02-04)
The inability of seasonal influenza vaccines to effectively protect against infection with antigenically drifted viruses or newly emerging pandemic viruses underlines the need for development of cross-reactive influenza vaccines that induce immunity against a variety of virus subtypes. Therefore, potential
Ying-Jie Lu et al.
Vaccine, 28(47), 7468-7475 (2010-09-23)
Mucosal immunization with a killed whole-cell pneumococcal vaccine, given with enterotoxin-related adjuvants, has been shown to confer multi-serotype protection against colonization of the nasopharynx and middle ear in mice. However, because novel mucosal immunization strategies may be difficult to implement
Joost P Uittenbogaard et al.
The Journal of biological chemistry, 286(42), 36198-36214 (2011-08-27)
β-Propiolactone is often applied for inactivation of viruses and preparation of viral vaccines. However, the exact nature of the reactions of β-propiolactone with viral components is largely unknown. The purpose of the current study was to elucidate the chemical modifications
Lucy A Perrone et al.
Journal of virology, 83(11), 5726-5734 (2009-03-27)
Influenza vaccines capable of inducing cross-reactive or heterotypic immunity could be an important first line of prevention against a novel subtype virus. Influenza virus-like particles (VLPs) displaying functional viral proteins are effective vaccines against replication-competent homologous virus, but their ability

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.